Squalamine Lactate for Exudative Age-Related Macular Degeneration

Ophthalmology Clinics of North America

Volumn 19, Issue 3, 2006, Pages 381-391

  Connolly, Brian ^a   Desai, Avinash ^b   Garcia, Charles A ^c   Thomas, Edgar ^d   Gast, Michael J ^b  

^a Retina Associates of Western New York   (United States)

^b Genaera Corporation   (United States)

^c Garcia and Associates   (United States)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[3 [(4 AMINOBUTYL)AMINO]PROPYL]AMINO] 7 HYDROXYCHOLESTAN 24 YLHYDROGENSULFATE BIS(2 HYDROXYPROPANOATE); ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZOPORPHYRIN DERIVATIVE; CALMODULIN; EVIZON; LACTATE DEHYDROGENASE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG UPTAKE; ENZYME BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA EXUDATE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; CHOLESTANOLS; EXUDATES AND TRANSUDATES; HUMANS; LACTATES; MACULAR DEGENERATION; TREATMENT OUTCOME;

EID: 33748787141     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2006.05.003     Document Type: Review

References (37)

1. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22 1 (2002) 6-18
2. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117 (1999) 1329-1345
3. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119 (2001) 198-207
4. Bressler N.M., Arnold J., Benchaboune M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120 (2002) 1443-1454
5. Harding S. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Eye 15 Pt 3 (2001) 407-412
6. Sharma S., Hollands H., Brown G.C., et al. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 36 (2001) 332-338
7. Congdon N., O'Colmain B., Klaver C.C., et al. Eye Diseases Prevalence Research Group: causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
8. Friedman D.S., O'Colmain B.J., Munoz B., et al. Eye Diseases Prevalence Research Group: prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
9. Klein R., Peto T., Bird A., et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 137 (2004) 486-495
10. Heier JS. Intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy for neovascular age-related macular degeneration: year 1 results. Presented at the ASRS 23rd Annual Meeting Scientific Program. Montreal, Ontario, Canada, July 16-20, 2005.
11. Miller JW. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Presented at the ASRS 23rd Annual Meeting Scientific Program. Montreal, Ontario, Canada, July 16-20, 2005.
12. Husain D., Kim I., Gauthier D., et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123 (2005) 509-516
13. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
14. Mosheghi AA. Durability of treatment effects in the Systemic Bevacizumab (Avastin) Therapy For Neovascular Age-Related Macular Degeneration (SANA) Study. Presented at the ASRS 23rd Annual Meeting Scientific Program. Montreal, Ontario, Canada, July 16-20, 2005.
15. Rosenfeld PJ. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration (SANA) Study: 12-week outcomes. Presented at the ASRS 23rd Annual Meeting Scientific Program. Montreal, Ontario, Canada, July 16-20, 2005.
16. Moore K.S., Wehrli S., Roder H., et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A 90 (1993) 1354-1358
17. Moriarty R.M., Enache L.A., Kinney W.A., et al. Stereoselective synthesis of squalamine des-sulfate. Tetrehedron Letters 36 (1995) 5139-5142
18. Moriarty R.M., Tuladhar S.M., Guo L., et al. Synthesis of squalamine, a steroidal antibiotic from the shark. Tetrehedron Letters 35 (1994) 8103-8106
19. Pechulis A.D., Bellevue III F.H., Cioffi C.L., et al. Synthesis of 24ξ-squalamine, an anti-infective steroidal polyamine. J Org Chem 60 (1995) 5121-5126
20. Jones S.R., Kinney W.A., Zhang X., et al. The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6 beta-hydroxy-3-aminosterols synthesized from hyodeoxycholic acid. Steroids 61 (1996) 565-571
21. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
22. Ferrara N., Gerber H., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
23. Spilsbury K., Garrett K.L., Shen W.Y., et al. Overexpression of VEGF in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157 (2000) 135-144 [Erratum: Am J Pathol 2000;157:1413]
24. Witmer A.N., Vrensen G.F., Van Noorden C.J., et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22 (2003) 1-29
25. Williams J.I., Weitman S., Gonzalez C.M., et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 7 (2001) 724-733
26. Li D., Williams J.I., and Pietras R.J. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 21 (2002) 2805-2814
27. Gorirn-Rivas M.J., Chen H.W., Marquez D.C., et al. Squalamine blocks tumor-associated angiogenesis and promotes antitumor effects of Herceptin in HER-2/neu-overexpression human breast cancer cells. Proc Am Assoc Cancer Res 43 (2002) 521-522
28. Sills Jr. A.K., Williams J.I., Tyler B.M., et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58 (1998) 2784-2792
29. Teicher B.A., Williams J.I., Takeuchi H., et al. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18 (1998) 2567-2573
30. Williams J. Squalamine: A new angiostaic steroid. In: Teicher B.A. (Ed). Antiangiogenic agents in cancer therapy (1998), Humana Press, Totawa (NJ) 153-174
31. Higgins R.D., Sanders R.J., Yan Y., et al. Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 1507-1512
32. Higgins R.D., Yan Y., Geng Y., et al. Regression of retinopathy by squalamine in a mouse model. Pediatr Res 56 (2004) 144-149
33. Ciulla T.A., Criswell M.H., Danis R.P., et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 23 (2003) 808-814
34. Genaidy M., Kazi A.A., Peyman G.A., et al. Effect of squalamine on iris neovascularization in monkeys. Retina 22 (2002) 772-778
35. Garcia C.A., Quiroz-Mercado H., Uwaydat S., et al. A phase I/II trial of squalamine lactate for the treatment of choroidal neovascularization in age related macular degeneration (ARMD). Invest Ophthalmol Vis Sci 45 (2004) E-Abstract 2362
36. Garcia C., Connolly B., Thomas E., et al. A phase 2 multi-dose pharmacokinetic study of EVIZON (squalamine lactate) for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration (AMD). [abstract 206] (2005), ARVO, Fort Lauderdale (FL)
37. Ciulla T, Rosberger D, Katz R, et al. AAO Annual Meeting, Chicago; October 15-18, 2005.